North Alabama Medical Center is proud to offer bamlanivimab/casirivimab and imdevimab therapy, a new monoclonal antibody treatment for eligible positive COVID-19 patients.
What is bamlanivimab/casirivimab and imdevimab or monoclonal antibody treatment?
Bamlanivimab/casirivimab and imdevimab is a monoclonal antibody treatment developed by pharmaceutical companies Eli Lilly and Regeneron Pharmaceuticals to help treat non-hospitalized patients with a mild or moderate case of COVID-19 (SARS-CoV-2). Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses. This therapy is designed to help block the COVID-19 virus and prevent the virus from further infecting healthy cells.
Bamlanivimab/casirivimab and imdevimab has received emergency use authorization (EUA) from the Food and Drug Administration (FDA) and is now being allocated by the U.S. Department of Health and Human Services (HHS) in partnership with the Alabama Department of Public Health and other state agencies.
Who is a candidate for monoclonal antibody treatment?
Adults and adolescents 12 years of age or older with mild to moderate symptoms who weigh 88 pounds (40 kg) or more, and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
Patients must meet specific clinical criteria including:
- Lab-confirmed COVID-19 positive test
- Stable enough to not require hospitalization
- Be within 10 days of symptom onset
In addition to meeting the above criteria, patients must also have an order from a provider to receive this treatment.
Who is not a candidate for this treatment?
This treatment will not be considered for patients who are currently hospitalized due to COVID-19, require oxygen therapy for COVID-19, and/or have a known hypersensitivity to bamlanivimab/ casirivimab and imdevimab.